Medscape8d
Short-Course Vaginal Brachytherapy Shows Comparable QOL Outcomes as Standard Treatment in Endometrial Cancer
Researchers compared QOL and other outcomes between patients with endometrial cancer who took short-course adjuvant VCB and ...
Medscape5d
Trop-2 Protein Overexpression is an Independent Marker for Predicting Disease Recurrence in Endometrioid Endometrial Carcinoma
Background Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially ...
Pharmaceutical Technology1d
Cadonilimab by Akeso for Endometrial Cancer: Likelihood of Approval
Cardinalizumab (Ketanil) is a bi-specific antibody acts as programmed death 1 protein (PD-1) antagonist and CTLA4 antagonist. It is formulated as solution for inravenous route of administration.
Pharmaceutical Technology1d
BGB-10188 by BeiGene for Endometrial Cancer: Likelihood of Approval
BGB-10188 is under clinical development by BeiGene and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success ...
Monthly Prescribing Reference12y
Vivelle-dot
Estradiol 0.025mg/day, 0.0375mg/day, 0.05mg/day, 0.075mg/day, 0.1mg/day; transdermal system. Increased risk of endometrial carcinoma or hyperplasia in women with intact uterus (adding progestin is ...
ascopubs.org13d
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma In this trial, patients with recurrent ...